Literature DB >> 16927162

Point-counterpoint: the importance of "open access" to psychotropics for our patients.

Alan D Schmetzer1, John J Wernert.   

Abstract

The opposing arguments regarding so-called "open access" to psychotropic medicines for all physicians are outlined, with references. The reader is left to draw conclusions from the discussion or to utilize the points in presentations to politicians, the media, pharmacy and therapeutics committees, state Medicaid agencies, etc.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16927162     DOI： 10.1007/s11126-006-9018-7

Source DB:  PubMed          Journal:  Psychiatr Q        ISSN： 0033-2720


  18 in total

1.  12-month outcome of patients with bipolar disorder following hospitalization for a manic or mixed episode.

Authors:  P E Keck; S L McElroy; S M Strakowski; S A West; K W Sax; J M Hawkins; M L Bourne; P Haggard
Journal:  Am J Psychiatry       Date:  1998-05       Impact factor: 18.112

Review 2.  The effects of early and sustained intervention on the long-term morbidity of schizophrenia.

Authors:  R J Wyatt; I D Henter
Journal:  J Psychiatr Res       Date:  1998 May-Aug       Impact factor: 4.791

Review 3.  Research policy implications of cost-of-illness studies for mental disorders.

Authors:  A Rupp; E M Gause; D A Regier
Journal:  Br J Psychiatry Suppl       Date:  1998

4.  The lifetime cost of bipolar disorder in the US: an estimate for new cases in 1998.

Authors:  C E Begley; J F Annegers; A C Swann; C Lewis; S Coan; W B Schnapp; L Bryant-Comstock
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 5.  Characteristics of materials distributed by drug companies. An evaluation of appropriateness.

Authors:  D Stryer; L A Bero
Journal:  J Gen Intern Med       Date:  1996-10       Impact factor: 5.128

6.  Cost of treating bipolar disorder in the California Medicaid (Medi-Cal) program.

Authors:  Jinmei Li; Jeffrey S McCombs; Glen L Stimmel
Journal:  J Affect Disord       Date:  2002-09       Impact factor: 4.839

7.  Effects of a limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia.

Authors:  S B Soumerai; T J McLaughlin; D Ross-Degnan; C S Casteris; P Bollini
Journal:  N Engl J Med       Date:  1994-09-08       Impact factor: 91.245

8.  The Maudsley bipolar disorder project. A survey of psychotropic prescribing patterns in bipolar I disorder.

Authors:  Sophia Frangou; Vanessa Raymont; David Bettany
Journal:  Bipolar Disord       Date:  2002-12       Impact factor: 6.744

9.  OPUS study: suicidal behaviour, suicidal ideation and hopelessness among patients with first-episode psychosis. One-year follow-up of a randomised controlled trial.

Authors:  M Nordentoft; P Jeppesen; M Abel; P Kassow; L Petersen; A Thorup; G Krarup; R Hemmingsen; P Jørgensen
Journal:  Br J Psychiatry Suppl       Date:  2002-09

Review 10.  Noncompliance with antidepressants: who's to blame?

Authors:  K Demyttenaere
Journal:  Int Clin Psychopharmacol       Date:  1998-02       Impact factor: 1.659
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.